ALLOZYNE

allozyne-logo

Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.

#SimilarOrganizations #People #Financial #Website #More

ALLOZYNE

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
2005-01-01

Address:
Seattle, Washington, United States

Country:
United States

Website Url:
http://www.allozyne.com

Total Employee:
11+

Status:
Active

Contact:
206-518-5700

Email Addresses:
[email protected]

Total Funding:
36.9 M USD

Technology used in webpage:
Viewport Meta Google Analytics Google Universal Analytics AJAX Libraries API U.S. Server Location Common Name Invalid PHP Sectigo SSL Sectigo Domain SSL Shockwave Flash Embed


Similar Organizations

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.


Current Advisors List

michael-steinmetz_image

Michael Steinmetz Board of Directors @ Allozyne
Board_member

steven-gillis_image

Steven Gillis Member of the Board of Directors @ Allozyne
Board_member

Current Employees Featured

not_available_image

Kenneth Grabstein
Kenneth Grabstein CSO @ Allozyne
CSO

Founder


david-a-tirrell_image

David A. Tirrell

dee-datta_image

Dee Datta

not_available_image

William A. Goddard

Investors List

ovp-venture-partners_image

OVP Venture Partners

OVP Venture Partners investment in Series B - Allozyne

alexandria-real-estate-equities_image

Alexandria Real Estate Equities

Alexandria Real Estate Equities investment in Series B - Allozyne

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series B - Allozyne

mpm-capital_image

MPM Capital

MPM Capital investment in Series B - Allozyne

arch-venture-partners_image

ARCH Venture Partners

ARCH Venture Partners investment in Series B - Allozyne

mpm-capital_image

MPM Capital

MPM Capital investment in Series A - Allozyne

arch-venture-partners_image

ARCH Venture Partners

ARCH Venture Partners investment in Series A - Allozyne

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series A - Allozyne

ovp-venture-partners_image

OVP Venture Partners

OVP Venture Partners investment in Series A - Allozyne

Official Site Inspections

http://www.allozyne.com

  • Host name: 115.130.96.66.static.eigbox.net
  • IP address: 66.96.130.115
  • Location: Burlington United States
  • Latitude: 42.509
  • Longitude: -71.1984
  • Metro Code: 506
  • Timezone: America/New_York
  • Postal: 01803

Loading ...

More informations about "Allozyne"

Allozyne - Wikipedia

Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic deโ€ฆSee details»

Allozyne Company Profile 2024: Valuation, Investors, โ€ฆ

Allozyne General Information Description. Provider of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and โ€ฆSee details»

ALLOZYNE Overview | SignalHire Company Profile

ALLOZYNE is a private company. The company currently specializes in the Biotechnology area. The position of the CEO is occupied by Meenu Chhabra ... Organization Website: โ€ฆSee details»

Allozyne, Inc. Company Profile | Seattle, WA - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Allozyne, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»

Allozyne Inc - Company Profile and News - Bloomberg Markets

Company profile page for Allozyne Inc including stock price, company news, executives, board members, and contact informationSee details»

Allozyne - Products, Competitors, Financials, Employees, โ€ฆ

Allozyne. Frequently Asked Questions (FAQ) When was Allozyne founded? Allozyne was founded in 2005. Where is Allozyne's headquarters? Allozyne's headquarters is located at 999 Third โ€ฆSee details»

Allozyne, Inc - VentureRadar

Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. ... Dansk Biotek โ€ฆSee details»

Allozyne - Company Profile - Tracxn

Allozyne - Protein therapeutics for CNS diseases such as multiple sclerosis.. Raised a total funding of $40.5M over 6 rounds from 6 investors. Founded by David Tirrell, Dee Datta and 1 โ€ฆSee details»

Allozyne - Funding, Financials, Valuation & Investors - Crunchbase

Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.See details»

Allozyne, Inc.:Company Profile & Technical Research,Competitor โ€ฆ

Allozyne, Inc. is a company that provides Pharmacy and Therapeutics, Multiple sclerosis, Peptide and more. Allozyne, Inc. is headquartered in United States Washington. Allozyne, Inc. was โ€ฆSee details»

ALLOZYNE Information - RocketReach

The NAICS codes for ALLOZYNE are [5417, 541, 54]. What is the SIC code for ALLOZYNE? The SIC codes for ALLOZYNE are [87, 873]. Top ALLOZYNE Employees Kenneth Grabstein Chief โ€ฆSee details»

ALLOZYNE - LinkedIn

At ALLOZYNE, we demonstrate this through both of our technology platforms as well as across our pipeline to target key disease areas. Both of our platforms enable the incorporation of โ€ฆSee details»

MedImmune acquires Allozyne - 2014-09-19 - Crunchbase

Allozyne Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. Acquiring Organization: MedImmuneSee details»

Allozyne, Inc - VentureRadar

Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. Using these โ€ฆSee details»

Allozyne Management Team - CB Insights

Allozyne and VLST have successfully raised Series B rounds ($55M and $30M respectively) and have "graduated" from Accelerator. Prior to joining OVP, Carl was a Venture โ€ฆSee details»

Allozymes

We can partner with pharmaceutical and manufacturing organizations. Life Sciences & Diagnostics. We are creating the next generation of enzymes which are the foundation to โ€ฆSee details»

Allozyne - Tech Stack, Apps, Patents & Trademarks - Crunchbase

Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. Search Crunchbase Start Free TrialSee details»

Allozymes Company Profile 2024: Valuation, Funding & Investors

Allozymes General Information Description. Developer of microfluidic technology designed to support the development and testing of enzymes. The company's platform helps employ โ€ฆSee details»

Allozyne, Inc. Sold For Scrap As MedImmune Snaps Up Rights

Sep 19, 2014 The drug stays in a patientโ€™s system longer and needs fewer doses, a boon to MS patients who have often have day-long infusion treatments. But Allozyne was competing in a โ€ฆSee details»

linkstock.net © 2022. All rights reserved